Teich Niels, Kleeff Jörg, Lochs Herbert, Mössner Joachim, Keim Volker, Friess Helmut, Ockenga Johann
Universität Leipzig, Medizinische Klinik und Poliklinik II, Leipzig, Germany.
BMC Gastroenterol. 2005 Jun 21;5:20. doi: 10.1186/1471-230X-5-20.
The proteolysis-inducing factor (PIF) was identified as a tumour product in various gastrointestinal cancers. A previous study in pancreatic cancer patients suggested PIF expression as a tumour marker, which is not related to tumour size. We hypothesized that PIF could be a useful marker to exclude benign pancreatic tumors, as chronic pancreatitis with a pancreatic mass.
Urine of patients with a pancreatic mass of uncertain malignancy was investigated for PIF expression by Western blot. Sufficient urine protein for analysis was available in 59 patients. The diagnosis was established by histology in 54 patients and by follow up in five patients with chronic pancreatitis. In addition, serum CA19-9 was measured.
The sensitivity (specifity) for the detection of a malignant pancreatic tumour was 90% (75%) and 54% (71%) for CA19-9 and PIF, respectively. The sensitivity (specifity) for the distinction of pancreatic cancer from chronic pancreatitis was 89% (80%) and 57% (63%) for CA19-9 and PIF, respectively.
Evaluation of PIF in urine is of no diagnostic value in patients with a pancreatic mass of unknown malignancy.
蛋白水解诱导因子（PIF）被鉴定为多种胃肠道癌症中的肿瘤产物。先前一项针对胰腺癌患者的研究表明，PIF表达可作为一种肿瘤标志物，且与肿瘤大小无关。我们推测PIF可能是排除良性胰腺肿瘤（如伴有胰腺肿块的慢性胰腺炎）的有用标志物。
通过蛋白质印迹法检测有恶性倾向的胰腺肿块患者尿液中的PIF表达。59例患者有足够的尿液蛋白用于分析。54例患者通过组织学确诊，5例慢性胰腺炎患者通过随访确诊。此外，还检测了血清CA19-9。
检测恶性胰腺肿瘤时，CA19-9和PIF的敏感性（特异性）分别为90%（75%）和54%（71%）。区分胰腺癌与慢性胰腺炎时，CA19-9和PIF的敏感性（特异性）分别为89%（80%）和57%（63%）。
对于有恶性倾向的胰腺肿块患者，检测尿液中的PIF无诊断价值。
